A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs GSK 1292263 (Primary) ; Atorvastatin; Ezetimibe
- Indications Dyslipidaemias
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
- 12 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 12 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History